{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:56:37Z","timestamp":1791219397390,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":200,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["218454\/Z\/19\/Z"],"award-info":[{"award-number":["218454\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Control of schistosomiasis depends on a single drug, praziquantel, with variable cure rates, high reinfection rates, and risk of drug resistance. A vaccine could transform schistosomiasis control. Preclinical data show that vaccine development is possible, but conventional vaccine efficacy trials require high incidence, long-term follow-up, and large sample size. Controlled human infection studies (CHI) can provide early efficacy data, allowing the selection of optimal candidates for further trials. A Schistosoma CHI has been established in the Netherlands but responses to infection and vaccines differ in target populations in endemic countries. We aim to develop a CHI for Schistosoma mansoni in Uganda to test candidate vaccines in an endemic setting. This is an open-label, dose-escalation trial in two populations: minimal, or intense, prior Schistosoma exposure. In each population, participants will be enrolled in sequential dose-escalating groups. Initially, three volunteers will be exposed to 10 cercariae. If all show infection, seven more will be exposed to the same dose. If not, three volunteers in subsequent groups will be exposed to higher doses (20 or 30 cercariae) following the same algorithm, until all 10 volunteers receiving a particular dose become infected, at which point the study will be stopped for that population. Volunteers will be followed weekly after infection until CAA positivity or to 12 weeks. Once positive, they will be treated with praziquantel and followed for one year. The trial registry number is ISRCTN14033813 and all approvals have been obtained. The trial will be subjected to monitoring, inspection, and\/or audits.<\/jats:p>","DOI":"10.1093\/immadv\/ltad010","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:16:38Z","timestamp":1689898598000},"source":"Crossref","is-referenced-by-count":5,"title":["Establishing a single-sex controlled human <i>Schistosoma mansoni<\/i> infection model for Uganda: protocol for safety and dose-finding trial"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6770-5588","authenticated-orcid":false,"given":"Andrew","family":"Abaasa","sequence":"first","affiliation":[{"name":"MRC\/UVRI & LSHTM Uganda Research Unit , Entebbe , Uganda"},{"name":"London School of Hygiene & Tropical Medicine , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses","family":"Egesa","sequence":"additional","affiliation":[{"name":"MRC\/UVRI & LSHTM Uganda Research Unit , Entebbe , Uganda"},{"name":"London School of Hygiene & Tropical Medicine , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuella","family":"Driciru","sequence":"additional","affiliation":[{"name":"MRC\/UVRI & LSHTM Uganda Research Unit , Entebbe , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Pieter R","family":"Koopman","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Kiyemba","sequence":"additional","affiliation":[{"name":"MRC\/UVRI & LSHTM Uganda Research Unit , Entebbe , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E","family":"Sanya","sequence":"additional","affiliation":[{"name":"MRC\/UVRI & LSHTM Uganda Research Unit , Entebbe , Uganda"},{"name":"African Population and Health Research Center , Nairobi , Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacent","family":"Nassuuna","sequence":"additional","affiliation":[{"name":"MRC\/UVRI & LSHTM Uganda Research Unit , Entebbe , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Ssali","sequence":"additional","affiliation":[{"name":"MRC\/UVRI & LSHTM Uganda Research Unit , Entebbe , Uganda"},{"name":"London School of Hygiene & Tropical Medicine , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geofrey","family":"Kimbugwe","sequence":"additional","affiliation":[{"name":"MRC\/UVRI & LSHTM Uganda Research Unit , Entebbe , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Wajja","sequence":"additional","affiliation":[{"name":"MRC\/UVRI & LSHTM Uganda Research Unit , Entebbe , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govert J","family":"van Dam","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L A M","family":"Corstjens","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-037X","authenticated-orcid":false,"given":"Stephen","family":"Cose","sequence":"additional","affiliation":[{"name":"MRC\/UVRI & LSHTM Uganda Research Unit , Entebbe , Uganda"},{"name":"London School of Hygiene & Tropical Medicine , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Seeley","sequence":"additional","affiliation":[{"name":"MRC\/UVRI & LSHTM Uganda Research Unit , Entebbe , Uganda"},{"name":"London School of Hygiene & Tropical Medicine , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorcas","family":"Kamuya","sequence":"additional","affiliation":[{"name":"Kenya Medical Research Institute (KEMRI) , Kilifi , Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily L","family":"Webb","sequence":"additional","affiliation":[{"name":"London School of Hygiene & Tropical Medicine , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Yazdanbakhsh","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontiano","family":"Kaleebu","sequence":"additional","affiliation":[{"name":"MRC\/UVRI & LSHTM Uganda Research Unit , Entebbe , Uganda"},{"name":"London School of Hygiene & Tropical Medicine , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afzal A","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Texas Tech University Health Sciences Center , Lubbock, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narcis","family":"Kabatereine","sequence":"additional","affiliation":[{"name":"Ministry of Health of Uganda , Kampala , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edridah","family":"Tukahebwa","sequence":"additional","affiliation":[{"name":"Ministry of Health of Uganda , Kampala , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meta","family":"Roestenberg","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M","family":"Elliott","sequence":"additional","affiliation":[{"name":"MRC\/UVRI & LSHTM Uganda Research Unit , Entebbe , Uganda"},{"name":"London School of Hygiene & Tropical Medicine , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"issue":"26","key":"2023080221031734800_CIT0001","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1016\/j.vaccine.2016.03.079","article-title":"Advancing a vaccine to prevent human schistosomiasis","volume":"34","author":"Merrifield","year":"2016","journal-title":"Vaccine"},{"issue":"7","key":"2023080221031734800_CIT0002","doi-asserted-by":"crossref","first-page":"e2865","DOI":"10.1371\/journal.pntd.0002865","article-title":"The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases","volume":"8","author":"Hotez","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"2023080221031734800_CIT0003","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S1473-3099(16)00175-4","article-title":"Outbreak of urogenital schistosomiasis in Corsica (France): an epidemiological case study","volume":"16","author":"Boissier","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"2023080221031734800_CIT0004","doi-asserted-by":"crossref","first-page":"e0009161","DOI":"10.1371\/journal.pntd.0009161","article-title":"Delayed diagnosis of spinal cord schistosomiasis in a non-endemic country: a tertiary referral centre experience","volume":"15","author":"de Wilton","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"9936","key":"2023080221031734800_CIT0005","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(13)61949-2","article-title":"Human schistosomiasis","volume":"383","author":"Colley","year":"2014","journal-title":"Lancet [Internet]"},{"issue":"12","key":"2023080221031734800_CIT0006","doi-asserted-by":"crossref","first-page":"e1396","DOI":"10.1371\/journal.pntd.0001396","article-title":"Examining the relationship between urogenital schistosomiasis and HIV infection","volume":"5","author":"Mbabazi","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"2023080221031734800_CIT0007","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/trstmh\/trt024","article-title":"Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda","volume":"107","author":"Tukahebwa","year":"2013","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"9","key":"2023080221031734800_CIT0008","doi-asserted-by":"crossref","first-page":"e1321","DOI":"10.1371\/journal.pntd.0001321","article-title":"Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review","volume":"5","author":"King","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"2023080221031734800_CIT0009","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.tmaid.2010.11.002","article-title":"Schistosomiasis in travellers and migrants","volume":"9","author":"Clerinx","year":"2011","journal-title":"Travel Med Infect Dis"},{"issue":"11","key":"2023080221031734800_CIT0010","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1586\/14787210.2013.844066","article-title":"Diagnosis and treatment of schistosomiasis in children in the era of intensified control","volume":"11","author":"Knopp","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"21","key":"2023080221031734800_CIT0011","doi-asserted-by":"crossref","first-page":"11537","DOI":"10.3390\/ijerph182111537","article-title":"Transmission dynamics of schistosoma haematobium among school-aged children: a cohort study on prevalence, reinfection and incidence after mass drug administration in the white nile state of sudan","volume":"18","author":"Jin","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"9","key":"2023080221031734800_CIT0012","first-page":"1151","article-title":"Reduced efficacy of praziquantel against Schistosoma mansoni is associated with multiple rounds of mass drug administration","volume":"63","author":"Crellen","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2023080221031734800_CIT0013","doi-asserted-by":"crossref","first-page":"e0005544","DOI":"10.1371\/journal.pntd.0005544","article-title":"Quantitative assessment of the impact of partially protective anti-schistosomiasis vaccines","volume":"11","author":"Alsallaq","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"2023080221031734800_CIT0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13071-017-2227-0","article-title":"Developing a mathematical model for the evaluation of the potential impact of a partially efficacious vaccine on the transmission dynamics of Schistosoma mansoni in human communities","volume":"10","author":"Stylianou","year":"2017","journal-title":"Parasites Vectors"},{"issue":"8","key":"2023080221031734800_CIT0015","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0169-4758(95)80041-7","article-title":"The irradiated cercariae vaccine model: looking on the bright side of radiation","volume":"11","author":"Richter","year":"1995","journal-title":"Parasitol Today"},{"issue":"7","key":"2023080221031734800_CIT0016","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1128\/IAI.01657-05","article-title":"Previous or ongoing schistosome infections do not compromise the efficacy of the attenuated cercaria vaccine","volume":"74","author":"Kariuki","year":"2006","journal-title":"Infect Immun"},{"key":"2023080221031734800_CIT0017","author":"WHO","year":"2014"},{"issue":"12","key":"2023080221031734800_CIT0018","doi-asserted-by":"crossref","first-page":"e0006968","DOI":"10.1371\/journal.pntd.0006968","article-title":"Safety and efficacy of the rSh28GST urinary schistosomiasis vaccine: a phase 3 randomized, controlled trial in Senegalese children","volume":"12","author":"Riveau","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"43","key":"2023080221031734800_CIT0019","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1016\/j.vaccine.2019.08.075","article-title":"A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area","volume":"37","author":"Keitel","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"2023080221031734800_CIT0020","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.pt.2016.10.010","article-title":"Sm-p80-based schistosomiasis vaccine: preparation for human clinical trials","volume":"33","author":"Siddiqui","year":"2017","journal-title":"Trends Parasitol"},{"issue":"7","key":"2023080221031734800_CIT0021","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1473-3099(15)00068-7","article-title":"Design, recruitment, and microbiological considerations in human challenge studies","volume":"15","author":"Darton","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"2023080221031734800_CIT0022","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41591-020-0759-x","article-title":"A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics","volume":"26","author":"Langenberg","year":"2020","journal-title":"Nat Med"},{"key":"2023080221031734800_CIT0023","doi-asserted-by":"crossref","first-page":"635985","DOI":"10.3389\/fimmu.2021.635985","article-title":"Immunological considerations for Schistosoma vaccine development: transitioning to endemic settings","volume":"12","author":"Driciru","year":"2021","journal-title":"Front Immunol"},{"key":"2023080221031734800_CIT0024","author":"PMA","year":"2020"},{"issue":"9930","key":"2023080221031734800_CIT0025","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(14)60817-5","article-title":"Uganda\u2019s struggle with schistosomiasis","volume":"383","author":"Loewenberg","year":"2014","journal-title":"The Lancet"},{"issue":"7","key":"2023080221031734800_CIT0026","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/infdis\/jiy275","article-title":"Establishing the production of male Schistosoma mansoni cercariae for a controlled human infection model","volume":"218","author":"Janse","year":"2018","journal-title":"J Infect Dis"},{"issue":"10","key":"2023080221031734800_CIT0027","doi-asserted-by":"crossref","first-page":"732","DOI":"10.7326\/L18-0438","article-title":"Katayama syndrome without Schistosoma mansoni eggs","volume":"170","author":"Langenberg","year":"2019","journal-title":"Ann Intern Med"},{"issue":"14","key":"2023080221031734800_CIT0028","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1017\/S0031182014000626","article-title":"Tools for diagnosis, monitoring and screening of Schistosoma infections utilizing lateral-flow based assays and upconverting phosphor labels","volume":"141","author":"Corstjens","year":"2014","journal-title":"Parasitology"},{"key":"2023080221031734800_CIT0029","first-page":"16","article-title":"Unfilled Vials","volume-title":"Science","author":"Cohen","year":"2016"},{"issue":"3","key":"2023080221031734800_CIT0030","doi-asserted-by":"crossref","first-page":"e637","DOI":"10.1371\/journal.pntd.0000637","article-title":"Influence of exposure history on the immunology and development of resistance to human Schistosomiasis mansoni","volume":"4","author":"Black","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"2023080221031734800_CIT0031","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-3083.1992.tb02878.x","article-title":"Immune responses during human schistosomiasis mansoni. XVIII. Immunologic status of pregnant women and their neonates","volume":"35","author":"Novato-Silva","year":"1992","journal-title":"Scand J Immunol"},{"issue":"7","key":"2023080221031734800_CIT0032","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1172\/JCI75429","article-title":"Immune activation alters cellular and humoral responses to yellow fever 17D vaccine","volume":"124","author":"Muyanja","year":"2014","journal-title":"J Clin Invest"},{"issue":"3","key":"2023080221031734800_CIT0033","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4269\/ajtmh.1996.54.265","article-title":"Protection against Schistosoma mansoni and associated immune responses induced in the vervet monkey Cercopithecus aethiops by the irradiated cercaria vaccine","volume":"54","author":"Yole","year":"1996","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"2023080221031734800_CIT0034","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/00034983.1967.11686489","article-title":"Quantitative aspects of exposure time and cercarial dispersion on penetration and maturation of Schistosoma mansoni in mice","volume":"61","author":"Warren","year":"1967","journal-title":"Ann Trop Med Parasitol"},{"key":"2023080221031734800_CIT0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.12688\/aasopenres.12841.2","article-title":"Ethical and scientific considerations on the establishment of a controlled human infection model for schistosomiasis in Uganda: report of a stakeholders\u2019 meeting held in Entebbe, Uganda","volume":"1","author":"Elliott","year":"2018","journal-title":"AAS Open Res"},{"issue":"1","key":"2023080221031734800_CIT0036","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/11287462.2022.2091503","article-title":"Ethical and practical considerations arising from community consultation on implementing controlled human infection studies using Schistosoma mansoni in Uganda","volume":"33","author":"Egesa","year":"2022","journal-title":"Glob Bioeth"},{"issue":"1","key":"2023080221031734800_CIT0037","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2471\/BLT.17.198879","article-title":"Praziquantel for the treatment of schistosomiasis during human pregnancy","volume":"96","author":"Friedman","year":"2018","journal-title":"Bull World Health Organ"},{"key":"2023080221031734800_CIT0038","volume-title":"Guidelines for the Treatment of Malaria.","author":"WHO","year":"2015"},{"issue":"2","key":"2023080221031734800_CIT0039","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.idc.2012.03.004","article-title":"Schistosomiasis","volume":"26","author":"Gryseels","year":"2012","journal-title":"Infect Dis Clin North Am"},{"issue":"6","key":"2023080221031734800_CIT0040","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jaad.2014.11.034","article-title":"Mucocutaneous manifestations of helminth infections: Nematodes","volume":"73","author":"Lupi","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"2023080221031734800_CIT0041","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/cid\/ciy761","article-title":"The impact of intensive versus standard anthelminthic treatment on allergy-related outcomes, helminth infection intensity, and Helminth-related morbidity in lake Victoria fishing communities, Uganda: results from the LaVIISWA cluster-randomized trial","volume":"68","author":"Sanya","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2023080221031734800_CIT0042","doi-asserted-by":"crossref","first-page":"e0005982","DOI":"10.1371\/journal.pntd.0005982","article-title":"Perceptions about interventions to control schistosomiasis among the Lake Victoria island communities of Koome, Uganda","volume":"11","author":"Sanya","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2023080221031734800_CIT0043","doi-asserted-by":"crossref","first-page":"17","DOI":"10.12688\/aasopenres.12972.1","article-title":"Risk assessment for the implementation of controlled human Schistosoma mansoni infection trials in Uganda","volume":"2","author":"Koopman","year":"2019","journal-title":"AAS Open Res"}],"container-title":["Immunotherapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/advance-article-pdf\/doi\/10.1093\/immadv\/ltad010\/50920044\/ltad010.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/3\/1\/ltad010\/51027007\/ltad010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/3\/1\/ltad010\/51027007\/ltad010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T21:04:29Z","timestamp":1691010269000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article\/doi\/10.1093\/immadv\/ltad010\/7227266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/immadv\/ltad010","relation":{},"ISSN":["2732-4303"],"issn-type":[{"value":"2732-4303","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2023,1,1]]},"article-number":"ltad010"}}